Breaking News, Financial News

Financial Report: Charles River Labs

Preclinical segment sales up 5% in the quarter

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Labs
 
1Q Revenues: $299.4 million (+3%)

1Q Earnings: $32.4 million (+26%)

Comments: RMS segment sales were $185.6 million in the quarter, up 2%, with growth in the Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $113.8 million, up 5% driven by continued demand from mid-tier biotechnology clients.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters